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Summary
Background Advances in neonatal intensive care have 
lowered the neonatal death rate. There are still some 
severely ill neonates and infants, however, for whom the 
application of all possible life-prolonging treatment 
modalities may be questioned.
Methods We did two studies in the Netherlands. In the first 
we sent questionnaires to physicians who had attended 
338 consecutive deaths (August-November, 1995) within 
the first year of life (death-certificate study), and in the 
second we interviewed 31 neonatologists or paediatric 
Intensive-care specialists and 35 general paediatricians* 
The response rates were 88% and 99%, respectively.
Findings in the death-certificate study, 57% of ali deaths 
had been preceded by a decision to forgo life-sustaining 
treatment; this decision was accompanied by the 
administration of potentially life-shortening drugs to 
alleviate pain or other symptoms in 23%, and by the 
administration of drugs with the explicit aim of hastening 
death in 8%. A drug was given explicitly to hasten death to 
neonates not dependent on life-sustaining treatment in 1% 
of all death cases. No chance of survival was the main 
motive in 76% of all end-of-life decisions, and a poor 
prognosis was the main motive in 18%. The interview study 
showed that parents had been involved in making 79% of 
decisions. The physicians consulted colleagues about 88% 
of decisions. Most paediatricians favoured formal review of 
medical decisions by colleagues together with ethical or 
legal experts.
Interpretation Death among neonates and infants is 
commonly preceded by medical end-of-life decisions. Most 
Dutch paediatricians seem to find prospects for survival 
and prognostic factors relevant in such decisions. Public 
control by a committee of physicians, paediatricians, 
ethicists, and legal experts is widely endorsed by 
paediatricians.
Lancet 1997; 350: 251-55
Introduction
Medical decision-making about the end of life for 
neonates and infants is under debate in the Netherlands. 
In 1995;, 190 000 babies were born alive in the 
Netherlands, and 1041 died within 1 year of birth. The 
neonatal death rate in the Netherlands is among the 
lowest in the world, which reflects favourable economic 
circumstances and high-quality health care for mothers 
and children. 29% of neonatal deadis occurred on the day 
of birth, and another 28% occurred within 1 week. Of all 
babies who died during the first week of Iife3 9% were 
born at gestational ages of less than 25 weeks, and 37% at 
gestational ages between 25 and 30 weeks. The cause of 
death was a perinatal disorder (such as perinatal asphyxia 
or complications of low birthweight) in 48 %3 and 
congenital malformations in 34%,
Although advances in medical knowledge and in 
neonatal intensive care have increased the possibilities of 
treating seriously affected infants, whether the application 
of every possible technique in all circumstances is 
appropriate is questionable.1’2 For neonates who are 
seriously ill and have a very poor prognosis for 
neurological function, the benefit of extending life is 
doubtful. In 1992, the Paediatric Association of the 
Netherlands issued a report on the different 
circumstances under which life-sustaining treatment may 
be withheld or withdrawn from neonates.3 It was 
recognised that there are very exceptional circumstances 
in which the intentional ending of life by administration 
of a lethal drug may be considered; the administration of 
potentially life**shortening drugs may be necessary for 
adequate terminal care. The intentional ending of life 
should, under Dutch law* be reported to the coroner to 
enable judicial examination. In 1995, three cases of 
intentional ending of life in neonates were reported.4
The Netherlands has 110 general hospitals that provide 
clinical paediatric care. Eight university hospitals and two 
large general hospitals have neonatal intensive-care units. 
Paediatricians attend about 80% of all hospital deaths 
among neonates and infants.
The aims of the present study were to give an overview 
of practices and attitudes about end-of-life decisions for 
neonates and infants in the Netherlands. The study 
paralleled an assessment of the judicial notification 
procedure for physician-assisted death, and was 
commissioned by the ministers of healtii and of justice.4,5
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Methods
We did two studies. In the first study we sent questionnaires to 
physicians who attended 338 consecutive deaths of neonates and 
infants to obtain estimates of the frequency of end-of-life 
decisions and their main characteristics. In the second study we 
interviewed 66 paediatricians in a stratified sample to obtain 
descriptions of the patients, physicianss and situations involved, 
and to investigate opinions about public control in end-of-life 
decision-making among Dutch paediatricians.
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Number replying “yes"
Neonatologists*
(n-31)"
Had withdrawn tlfo-sustnlnlng treatment
No chance of survival 
Poor prognosis for later life
Had withheld life-sustaining treatment
No chance of survival 
Poor prognosis for later life
Had administered drug with explicit Intention 
of ending llfe| |
Ever administered
Never administered, but could conceive 
of situations in which they would 
Would never administer, but would refer to 
another physician
Would never administer or refer patient
General
paediatricians
(n=35)
31 ( 100%) 
30(97%)
23 ( 68%) t  
14 (4 0 % ) I
20(67%)
17(55%)
21 (66%)* 
1 0 (30%)§
14(45%)
9 ( 29%)
6 (21%) t
l(496)t
1 1 (3 1 % ) 
17 (49%)
6 (20%)f
0
♦Neonatologists and intensive-care specialists. fAnswers m issing for one participant. 
^Answers missing for three participants. gAnswers missing for tw o  partic ipants. 
HWhether or not after a preceding decision to forgo Nfe-sustaining treatm ent.
Table 1: Paediatricians’ statements about th e ir  p ra c tic e s  for 
end-of-life decisions (interview study)
Death-certificate study
The causes of death for all inhabitants o f the N etherlands are 
reported to Statistics Netherlands. Patients are n o t  m entioned by 
name on the cause-of-death forms, but the nam es o f the 
reporting physicians arc given. Details of 338 con secu tive deaths 
in children aged under 1 year between A ugust an d  November, 
1995, were obtained (32% of 1041 deaths in  th is age-group in 
1995). For 26 deaths, no medical decision about th e  end o f  life 
could have been, made (for example, in su d d en  infant death 
syndrome), and no questionnaire was sent. Q uestionnaires were 
sent to physicians for the remaining 312 d eath s. T o ensure 
anonymity of the physicians and the patients^ questionnaires 
were coded and contained no identifying inform ation. Codes 
were removed by the notary to whom the questionnaires were 
sent by the responders. 299 (88%) questionnaires w ere returned. 
The questionnaires consisted of 23 questions. K.ey questions 
were whether life-sustaining treatment had b een  withheld or 
withdrawn, whether a potentially life-shortening drug had been 
used, and whether these acts had been intended to  hasten death. 
Results were weighted for non-response for age3 sex , and cause 
and place of death.
interview study
We interviewed neonatologists, paediatric intensive-care 
specialists and general paediatricians face to face; interviewees 
were randomly selected from the national official register. Since 
death among neonates mainly occurs in in tensive-care units, we 
aimed to interview a third of all 77 D utch neonatologists or 
intensive-care specialists, and a similar n u m b er o f general 
paediatricians (out of about 600). To be selected* paediatricians 
had to have been practising in their speciaky since at least Jan 1, 
1994, and to have worked at the same institution since then. Of 
32 neonatologists or intensive-care specialists w h o  w ere invited to 
participate, one did not meet this criterion^ o f  38 general 
paediatricians, two did not meet this criterion and o n e  refused to
% of c a s e s *
take part in the study (99% response rate). Therefore, we 
interviewed 31 neonatologists or intensive-care specialists and 35 
general paediatricians. These 66 physicians attended about a 
quarter of all deaths among children aged under 1 year during 
1995 in the Netherlands.
The classification of end-of-life decisions was primarily based 
on the type of practice done or not done and, by contrast to the 
death-certificate study, on the prognosis for the infant. 
Interviewees were asked if: they had ever withdrawn or withheld 
life-sustaining treatment from an infant because there was no 
chance of survival, or because of an extremely poor prognosis for 
later life; or if they had ever administered a drug to an infant 
explicitly to hasten the end of life.
The forgoing of life-sutaining treatment was defined as 
“withdrawing or withholding every medical or surgical treatment 
aimed at prolonging life”; palliative care (eg, hydration, provision 
of warmth, pain relief) may have been continued after such a 
decision. For each of these decisions the last such death, if any, 
was discussed and interviewees were asked to consult medical 
chans during the interview. At the end of the interview, questions 
were asked about the interviewee’s opinions on end-of-life 
decision-making in neonatology and on review procedures for 
these decisions.
Six experienced physicians each interviewed 10-15 
paediatricians; the interviewers were trained in interview skills, to 
use our structured questionnaire, and to explain key terms, An 
appraisal was made of each interview by the interviewer and an 
investigator (AvdH). The interviews lasted 2*5 h on average. To 
obtain valid estimates for the Netherlands, we calculated weights 
based on the proportion of neonatologists and intensive-care 
specialists who were represented in the sample, and on the 
proportion of all deaths among children aged under 1 year that 
the general paediatricians had attended.
Results
Death-certificate study
Of all deaths among children aged under 1 year in this 
study (n=299), 36% occurred in a neonatal intensive-care 
unit  ^ 51% in a hospital but not in a neonatal intensive- 
care unit, and 14% not in hospital.
In 24% of cases, death occurred suddenly and 
unexpectedly, and in 14% treatment was continued until 
death. In the remaining 62%, an end-of-life decision 
preceded death. This percentage varied with the place of 
death; for neonatal intensive-care units it was 87%, for 
deaths in other hospital departments (mostly paediatric 
wards) 56%, and for deaths not in hospital 21%.
In 57% of cases, death was preceded by the withdrawal 
or withholding of life-sustaining treatment. Most of these 
decisions were made because there was no chance of 
survival (77%) or a poor prognosis for later life (18%); 
5% could not be assigned to either category. In 23% of all 
deaths, the decision to forgo treatment was followed by 
the administration of drugs (generally opioids) to alleviate 
pain and symptoms, in doses that may have shortened
Im m aturity Complications Congenital abnormalities Perinatal Acquired
o f prematurity
CNS Heart Multiple Other
asphyxia
1
diseases
Life-sustaining treatment withdrawn
No chance of survival (n=49)
Poor prognosis (n=36)
1 ( 1% ) 
0
9 (14%) 
14(33 % )
1(1%)
5 ( 13%)
5 {14%) 
0
11(31%) 
4(18%)
7 (9%) 
2(3%)
7(18%) 
9 (31%)
8 (13%) 
2 ( 3%)
Llfo-sustnlnlng treatment withheld
No chance of survival (n=36)
Poor prognosis (n=22)
7 (24%) 
3 (22%)
3 (6 % )
2 ( 12%)
7 ( 24%) 
6 ( 20%)
4(7%)
0
13 (33%) 
6 (28%)
1 (1%) 
3(6%)
0
1 (10%)
1 (4%) 
1(2%)
Drug administered with explicit Intention of 0 1 (2 % ) 6 ( 35%) 1 (8%) 6 (29%) 1(8%) 6 ( 16%) 1(2%)
ending life (n=22)t
CNS^central nervous system. *Row percentages shown based on w e igh ted  data. tWhether or not after a preceding decision to forgo life-sustaining treatment.
Table 2: Diagnosis in neonates and infants in w h o m  death was preceded by a medicai end-of-life decision (interview study)*
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Number replying "yes"
Not conceivable without approval of parents
To forgo life-sustaining treatment because of poor prognosis 
To administer a drug with explicit intention of ending life
Approval of parents Important for careful decision-making
To forgo life-sustaining treatment because of poor prognosis 
To administer a drug with explicit intention of ending life
Forgoing of life-sustaining treatment Is a medical decision that has to be reviewed
All cases 
Some cases 
No cases
Administration of a drug explicitly to end life Is a medical decision that has to be reviewed
Ali cases 
Some cases
Administration of a drug explicitly to end life Is a medical decision that has to be reviewed
Before
After
Both_________________________________________________________________________
Administration of a drug explicitly to end life Is a medical decision that has to be reviewed before intervention^
By caregivers Involved
By Independent medical professionals
By committee not restricted to medical professionals
By public prosecutorg
By others
Administration of a drug explicitly to end life Is a medical decsion that has to be reviewed after Intervention!!
By caregivers involved 
By independent medical professionals 
By committee not restricted to medical professionals 
By public prosecutorg 
By others
Neonatologists/paediatric General
intensive-care specialists paediatricians
(n=31) (n=35)
28 ( 93%) * 27(77%)
31(100%) 27 (77%)
28 (97%)f 32 (91%)
29 ( 100%) * 34(100%)*
16(52%)
*
18 (51%)
11(36%) 12(34%)
4 ( 13%) 5 (14%)
29(94%)
«
32 (91%)
2 (7%) 3(9%)
11(36%) 12 (35%)
7 ( 23%) 2(6%)
13 (42%) 20(59%)*
11 (46%) 19 (59%)
19(79%) 21 (66%)
18 (75%) 18 (56%)
1(4%) 2(6%)
0 1(3%)
4 (20%) 7 (32%)
11 (55%) 13 (59%)
15(75%) 13 (59%)
2 ( 10%) 1(5%)
2 ( 10%) 4 ( 18%)
♦Answers not available for one participant. tAnswers not available for two participants, ^More than one answer allowed; n=24 for neonatologists; n=32 for general paediatricians. 
§This category was not offered for control before administration, but nevertheless mentioned by some respondents. ||More than one answer allowed; n=20 for neonatologists; n-22 
for general paediatricians.
Table 3: Paediatricians' statements about decision-making (interview study)
life. The estimated shortening of life was less than 1 
month in 84% of babies and more than 1 month in 11% 
(in 4% the length of time could not be estimated). In 8% 
of deaths, the decision to forgo life-sustaining treatment 
was combined with drugs given explicitly to hasten death. 
Life was shortened by less than 1 month in 67% and by 
more than 1 month in 33% of babies. In 26% of cases, no 
drug with a potentially life-shortening effect was given.
In 4% of all deaths, the only decision made had been to 
give drugs to alleviate pain and symptoms in doses that 
may have shortened life. These decisions were not made 
because of prognosis for later life in any case; life was not 
shortened by more than 1 week.
The decision to give a drug explicitly to hasten death to 
an infant not dependent on life-sustaining treatment 
preceded 1% of deaths; if the deaths in this study are 
representative of a whole year, this proportion represents 
10-15 deaths of this type per year in the Netherlands.
Interview study
When interviewed, most paediatricians said that they had 
withdrawn or withheld life-sustaining treatment from a 
neonate or infant at least once (table 1). More 
interviewees had done this because there was no chance 
of survival than because of a poor prognosis for later life. 
26% of the general paediatricians had never withdrawn 
life-su staining treatment, but could conceive of situtaions 
in which they would be prepared to do so; similarly, 
for withholding treatment 16% of neonatologists or 
intensive-care specialists and 23% of general 
paediatricians would be prepared to do so. 45% and
31%, respectively, had given drugs explicitly to end life, 
irrespective of whether a preceding decision to forgo life- 
sustaining treatment had been made. Furthermore, 29% 
of neonatologists or intensive-care specialists and 49% of 
general paediatricians who had not done so could 
conceive of situations in which they would give such 
drugs. Only one respondent (an intensive-care specialist) 
was unable to give drugs to end life or refer patients to a 
colleague prepared to do so.
Table 2 shows farther details for the last cases in which 
an end-of-life decision was made. Congenital abnormality 
was the most frequent diagnosis for which life-sustaining 
treatment was forgone (56%). Complications of 
premature birth or immaturity were the main diagnoses 
in a third of the cases—immaturity mainly for the 
withholding of treatment and prematurity mainly for the 
withdrawal of treatment. Among babies for whom 
treatment was withdrawn or withheld because there was 
no chance of survival, the estimated shortening of life was 
less than 1 month in 73% and 95%, respectively (less 
than 24 h in 47% and 65%, respectively); among babies 
for whom treatment was withdrawn or withheld because 
of poor prognosis, life was shortened by less than 1 
month in 31% and 10%, and more than 6 months in 
30% and 26%, respectively.
Decisions to give drugs explicitly to end life were made 
for 48% in infants among whom life-sustaining treatment 
had earlier been forgone. Congenital defects of 
the central nervous system, multiple congenital 
abnormalities, and perinatal asphyxia were the most 
frequently involved diagnoses. Life was shortened by less 
than 1 month in 63%, and more than 5 years among 16%
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of babies. In all of the latter babies, severe brain damage* 
precluded favourable neurological outcome.
Parents were involved in 79% of decisions. End-of-life 
decisions never went against parental wishes in these 
cases. The most common reason for not involving parents 
was that “it was so obviously the only correct decision”. 
Consultation of colleagues was also common and 
occurred in 88% of cases* (In the death-certificate study3 
89% of end-of-life decisions were discussed with parents 
and 81% with colleagues.)
• Approval of parents was thought to be important for 
careful decision-making (table 3), 23% of the general 
paediatricians j however, thought that the forgoing of life- 
sustaining treatment and the administration of a drug 
explicitly to end life can very occasionally, occur without 
the parents* approval. The most common reason for this 
answer among interviewees was that parents should not in 
every case be forced to share the responsibility to forgo 
treatment; and that some parents are not able to judge the 
child’s prognosis adequately.
Only one of the cases discussed of actively ending an 
infant’s life had been reported for judicial examination. 
Although almost all paediatricians thought that decisions 
to end an infant’s life by administration of a drug should 
be reviewed by some form of public control^ not all 
judged this to be relevant in all or some cases of forgoing, 
life-sustaining treatment (table 3). Opinions varied on 
whether review should take place before or after the event. 
Of the respondents who thought review should always 
occur for the decision to end an infant’s life by 
administration of a drug, most thought that independent 
medical professionals are best equipped to do the review5 
possibly together with legal and ethical experts. The 
public prosecutor was thought to be the proper reviewing 
authority by only a few respondents, although such review 
forms the core of the current judicial notification 
procedure for physician-assisted death.
Discussion
This overview is based on two national studies with high 
response rates. The willingness to cooperate in this study 
may have been increased by letters that were sent before 
the start to all paediatricians by the president of the Royal 
Dutch Medical Association and the Chief Inspector for 
Health Care, and by the president of the Paediatric 
Society of the Netherlands. These letters explained the 
aims of the studies and emphasised the importance of 
cooperation. Immunity from legal prosecution was also 
guaranteed in relation to all data collected.
Empirical studies on medical end-of-life decisions in 
neonates and infants are scarce. Studies in the USA and 
Denmark (published between 1973 and 1989) found that 
life-sustaining treatment had been withdrawn or withheld 
in between 10% and 20% of cases.6-8 Whitelaw9 reported a 
substantially larger treatment withdrawal rate of 70% 
among 75 prospectively followed newborn infants in an 
intensive-care unit in the UK, High frequencies (86% and 
82%) of treatment withdrawal were reported in two 
studies from Canada and the U SA .10,11 Since the advances 
in medical technology and neonatal intensive care have 
occurred mainly in the past two decades, the differences 
between these studies may be due partly to when they 
were done. Three studies on end-of-life decision-making 
in neonatology12"14 have been done in the Netherlands. In 
four intensive-care units12,13 in 1990 and 1993, life-
sustaining treatment was forgone in 59% and 81% of all 
deceased infants, respectively. In the third study, all 
deaths during 1990-94 in one neonatal intensive-care unit 
were analysed. 80% of deaths immediately followed the 
withdrawal of artificial ventilation, and additional sedative 
drugs were given to all these babies. 18% of deaths were 
spontaneous, as expected, and 2% of deaths were caused 
by the intentional administration of a lethal dose of a 
drug. In all these studies, two-thirds of the end-of-life 
decisions were made because there was no charice of 
survival.
In our study, which includes deaths in intensive-care 
units and elsewhere throughout the Netherlands, medical 
end-of-life decisions preceded 62% of all deaths in 
children aged under 1 year, mostly involving the 
withholding or withdrawal of life-sustaining treatment. In 
neonatal intensive-care units, the frequency was 87%, 
which confirms results from the previous studies in 
intensive-care units. Although end-of-life decisions are 
less common in other settings^ they are not exceptional.
The international debate on end-of-life decisions in 
neonatology often focuses on the acceptability of motives 
that are not exclusively medical in making decisions. 
When there is no chance of survival and treatment is futile 
according to current medical standards, physicians are 
morally and legally entitled to withhold or withdraw life- 
sustaining treatment.i5>16 In the USA, other factors were 
excluded from end-of-life decision-making in die Baby 
Doe regulations, although subsequent comments suggest 
that these regulations in fact illustrate that diese other 
factors cannot be ignored^ since they state that an 
irreversible coma warrants the withdrawal of treatment.17,18 
Dutch paediatricians seemed in our study to promote 
quality-of-life considerations as an important reason to 
forgo life-sustaining treatment in a substantial number of 
cases. This type of argument is also deemed to be 
acceptable by many of the Dutch paediatricians, although 
the legal implications of this practice are not completely 
clear, as is true for the role of parents. Although in the 
Netherlands end-of-life decisions are judged to be 
medical decisions for which physicians are initially 
responsible,16 parents are, if possible, involved in making 
decisons, and when they are, end-of-life decisions are not 
made without their consent.
Studies that include decisions abut administration of 
potentially life-shortening drugs, whether or not a 
decision was made to forgo life-sustaining treatment, are 
rare. The hastening of death mostly occurs as the 
inevitable but not desired result of the alleviation of pain 
or symptoms. In the main, drugs were administered 
explicitly to hasten the deaths of infants for whom life- 
sustaining treatment had been forgone previously. In most 
of these cases the administration of drugs was thought to 
be unavoidable to ensure good clinical practice in 
terminal care.3 This type of practice probably explains the 
large proportion of paediatricians who admitted in our 
interview study that they had given life-shortening drugs. 
A straightforward distinction between the active ending of 
life and provision of terminal care that intentionally or 
unintentionally hastens death may not always be easy to 
make. The administration of a drug explicitly to hasten 
the death of an infant not dependent on life-sustaining 
treatment is rare in the Netherlands.
The administration of a drug to an infant to hasten 
death is subject to criminal law in the Netherlands, and 
should, as physician-assisted death, be reported to the
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coroner to enable judicial examination. Physicians who 
act in accordance with accepted practice, as formulated 
by courts and the medical profession, will not be 
prosecuted.19 However, the consequences of reporting 
physician-assisted death in an incompetent patient, such 
as an infant, remain unclear. Two physicians were 
prosecuted for assisting in the death of a neonate; both 
were acquitted because the acts were deemed to be 
medically necessary. Physician-assisted death for neonates 
is, however, virtually never reported. Nevertheless, the 
open debate in the Netherlands on euthanasia and related 
practices in neonatology provided conditions under which 
these practices could be thoroughly investigated. No 
similar data about the administration of life-shortening 
drugs are available from other countries.
A study of physician-assisted death in the Netherlands 
showed that the frequency of euthanasia (ie, 
administration of a drug given intentionally to end life at 
the patient’s explicit request) increased from about 1-8% 
in 1990 to about 2*4% in 1995; medical backgrounds of 
patients remained virtually unchanged and the adherence 
to guidelines improved.'1*5’20 The frequency of ending life 
without the patient’s explicit request, which is sometimes 
identified as undesirable and resulting from a liberal 
attitude towards euthanasia and physician-assisted 
suicide, decreased from 0*8% to 0*7%. The current 
judicial notification procedure was, therefore, thought to 
have at least partly achieved its goals of stimulating 
openness and careful practice without evoking 
undesirable side-effects. Whether this conclusion is 
applicable to neonates cannot be decided from our study. 
The results should be viewed in the light of the low 
neonatal mortality rate in the Netherlands, which limits 
their applicability to other populations. Among neonates, 
life-sustaining treatment in many cases has to be started 
before the prognosis and the future quality of life can be 
assessed without sufficient certainty. We found that 
decisions to withhold or withdraw life-sustaining 
treatment, or, rarely, to give life-shortening drugs, seemed 
to occur only when diagnostic tests and the response of 
the patient to treatment showed that, despite medical 
possibilities, chances of long-term survival were absent or 
that the prognosis for later life was extremely poor.
Nearly all paediatricians believed that some form of 
public control on decision-making about the end of life in 
neonates is necessary. Nevertheless, the current judicial 
notification procedure was rejected by most 
paediatricians. In the Netherlands, two working groups 
commissioned by the government are studying possible 
conditions for end-of-life decision making, and the 
required forms of public control in this area and the 
related topic of late pregnancy termination (after 24 
weeks). A formal procedure by which cases are reviewed 
before or after death by independent colleagues and other 
experts, and only in exceptional cases referred for judicial 
review, will probably result in more effective public 
control.
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